These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37535747)

  • 1. Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target.
    Wang K; Zhang Z; Hang J; Liu J; Guo F; Ding Y; Li M; Nie Q; Lin J; Zhuo Y; Sun L; Luo X; Zhong Q; Ye C; Yun C; Zhang Y; Wang J; Bao R; Pang Y; Wang G; Gonzalez FJ; Lei X; Qiao J; Jiang C
    Science; 2023 Aug; 381(6657):eadd5787. PubMed ID: 37535747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbial gatekeepers: unraveling the role of the gut microbiota enzyme DPP4 in diabetes management.
    Liao L; Lin F; Gao J
    Trends Biochem Sci; 2024 Feb; 49(2):99-100. PubMed ID: 37770288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbial-host-isozyme: unveiling a new era in microbiome-host interaction.
    Miao L; Tilg H; Zheng MH
    Gut Microbes; 2023 Dec; 15(2):2267185. PubMed ID: 37815552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota DPP4-like enzymes are increased in type-2 diabetes and contribute to incretin inactivation.
    Olivares M; Hernández-Calderón P; Cárdenas-Brito S; Liébana-García R; Sanz Y; Benítez-Páez A
    Genome Biol; 2024 Jul; 25(1):174. PubMed ID: 38961511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Hikida K; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Minami M; Shiotani M
    J Pharmacol Sci; 2016 Dec; 132(4):255-261. PubMed ID: 27889414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction.
    Esposito G; Cappetta D; Russo R; Rivellino A; Ciuffreda LP; Roviezzo F; Piegari E; Berrino L; Rossi F; De Angelis A; Urbanek K
    Br J Pharmacol; 2017 Nov; 174(22):4070-4086. PubMed ID: 27922176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis.
    Mulvihill EE; Varin EM; Gladanac B; Campbell JE; Ussher JR; Baggio LL; Yusta B; Ayala J; Burmeister MA; Matthews D; Bang KWA; Ayala JE; Drucker DJ
    Cell Metab; 2017 Jan; 25(1):152-165. PubMed ID: 27839908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dipeptidyl peptidase-4 inhibition in vivo: Dipeptidyl peptidase-4 inhibitor/gut microbiome crosstalk suggests novel therapeutic options for diabetes management.
    Yasuda T; Harada N; Inagaki N
    J Diabetes Investig; 2024 Jun; 15(6):704-706. PubMed ID: 38323861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Binding Study of Gliptins to Bacterial DPP4-like Enzymes for the Treatment of Type 2 Diabetes Mellitus (T2DM).
    Carpio LE; Olivares M; Benítez-Paez A; Serrano-Candelas E; Barigye SJ; Sanz Y; Gozalbes R
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a
    Yazbeck R; Jaenisch S; Squire M; Abbott CA; Parkinson-Lawrence E; Brooks DA; Butler RN
    Sci Rep; 2019 Mar; 9(1):4906. PubMed ID: 30894647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.
    Sternkopf M; Nagy M; Baaten CCFMJ; Kuijpers MJE; Tullemans BME; Wirth J; Theelen W; Mastenbroek TG; Lehrke M; Winnerling B; Baerts L; Marx N; De Meester I; Döring Y; Cosemans JMEM; Daiber A; Steven S; Jankowski J; Heemskerk JWM; Noels H
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e65-e77. PubMed ID: 31893947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
    Sauvé M; Ban K; Momen MA; Zhou YQ; Henkelman RM; Husain M; Drucker DJ
    Diabetes; 2010 Apr; 59(4):1063-73. PubMed ID: 20097729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of DPP4 enhances inhibitory synaptic transmission through activating the GLP-1/GLP-1R signaling pathway in a rat model of febrile seizures.
    Zhang Y; Liu Y; Xu J; Sun Q; Yu F; Cheng J; Peng B; Liu W; Xiao Z; Yin J; Han S; He X
    Biochem Pharmacol; 2018 Oct; 156():78-85. PubMed ID: 30086287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY.
    Guida C; McCulloch LJ; Godazgar M; Stephen SD; Baker C; Basco D; Dong J; Chen D; Clark A; Ramracheya RD
    Diabetes Obes Metab; 2018 Mar; 20(3):571-581. PubMed ID: 28892258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
    Wang A; Dorso C; Kopcho L; Locke G; Langish R; Harstad E; Shipkova P; Marcinkeviciene J; Hamann L; Kirby MS
    BMC Pharmacol; 2012 Apr; 12():2. PubMed ID: 22475049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice.
    Li Z; Fang J; Jiao R; Wei X; Ma Y; Liu X; Cheng P; Li T
    Biomed Pharmacother; 2017 May; 89():1467-1475. PubMed ID: 28376584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPP4 inhibitors: a new approach in diabetes treatment.
    Doupis J; Veves A
    Adv Ther; 2008 Jul; 25(7):627-43. PubMed ID: 18641927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of molecular interaction of sitagliptin with human DPP
    Gonzatti MB; Júnior JEM; Rocha AJ; de Oliveira JS; Evangelista AJJ; Fonseca FMP; Ceccatto VM; de Oliveira AC; da Cruz Freire JE
    Adv Med Sci; 2023 Sep; 68(2):402-408. PubMed ID: 37837799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.